Navigation Links
Scarred for Life? Synedgen Hopes Not
Date:6/4/2013

Claremont, CA (PRWEB) June 04, 2013

Because burns tend to heal slowly, become infected and remain inflamed, they can produce scars that are excessive, physically debilitating and functionally damaging. Each year in the US, more than 1 million burn injuries require medical attention. While over the last several decades advances in life saving technology have improved outcomes for burn patients, methods to prevent scar formation have not kept pace.

With support from the US Army Medical Research and Materiel Command, Synedgen is working to accelerate the burn healing process. This contract will expand Synedgen’s pipeline wound care portfolio and facilitate studies to further demonstrate the extent of Synedgen’s novel polysaccharide derivative to reduce inflammation and provide enhanced healing with the reduction of scarring. Funding will also support analysis of cellular mechanisms of scar formation and how the product mitigates this process.

“There is an urgent need to address wound healing and scar reduction in burn patients, and we are eager to continue our product development to improve outcomes for these patients,” stated Synedgen president Shenda Baker. “Synedgen’s product has been demonstrated in vivo and in vitro to reduce inflammation and infection in dermal wounds and to increase healing with significant reduction of scar tissue. The product is designed to control the inflammation, both due to tissue damage and to bacteria, and accelerate the regenerative environment to prevent the emergence of excessive scar formation.”

This work is supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-13-C-0053. The views, opinions and/or findings contained in this release are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

About Synedgen

Synedgen Inc. is an innovative pharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10796834.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Synedgen Announces Issuance of Patent to Optimize Animal Health
3. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):